exRNAdisease

General Information

Database ID:

exR0083926

RNA Name:

UBB

RNA Type:

mRNA

Chromosome:

chr17

Starnd:

Coordinate:

Start Site(bp):

16380798

End Site(bp):

16382745

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ABCF2	chr7	151207837	151227166	-
ABRACL	chr6	139028745	139043302	+
AC005258.1	chr19	2269525	2341172	+
AC006064.6	chr12	6556886	6607367	-
AC008763.3	chr19	7678501	7682854	+
AC010422.3	chr19	12643831	12648397	-
AC026954.2	chr17	7312661	7319174	-
AC027644.4	chr7	66628958	66811189	+
AC104452.1	chr3	49416777	49429314	-
ACIN1	chr14	23058564	23095614	-
ACLY	chr17	41866917	41930542	-
ACTB	chr7	5527148	5563784	-
ACTG1	chr17	81509971	81523847	-
ADARB1	chr21	45073853	45226560	+
ADCY6	chr12	48766194	48789037	-
AGBL5	chr2	27042364	27070622	+
AGPAT4	chr6	161129967	161274061	-
AK2	chr1	33007940	33080996	-
AKR1A1	chr1	45550543	45570049	+
AKR7A2	chr1	19303965	19312146	-
AL136454.1	chr1	192716132	192716653	+
AL136531.2	chr20	1317571	1393096	-
ALDOA	chr16	30064164	30070457	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-4426	chr1	192716333	192716349	+

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC006064.5	chr12	6510275	6510522	+
AC008014.1	chr12	46383652	46876784	+
AC069281.2	chr7	100572232	100578700	-
AC073062.1	chr2	13537673	13609168	+
AC107959.2	chr8	23068229	23083619	+
AC126365.1	chr17	20788071	20789584	+
AD000090.1	chr19	35557956	35581954	+
AL117378.1	chr6	131901963	131920565	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference